"name","instanceType","uuid:ID","rationale","id","description","label"
"Study Design 1","StudyDesign","70d50e17-6e46-4abb-b37f-c370c6c5a2c1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign_1","The main design for the study",""
